HAVE QUESTIONS?

THE ANSWERS TO SOME COMMON QUESTIONS

The C-Eye device

The C-Eye device is a portable, battery powered UV irradiation device that can be used to cross-link corneas – either in the OR, or at the slit lamp. 

The price for the device and related product line will be determined by your national distributor. Please contact your national distributor directly when the product line becomes available. In the future, you will be able to find your country’s distributor on our website. To get notified of changes, you can subscribe to our newsletter via our website.

The C-Eye device will first be available in the Middle East and Northern Africa in 2019; other countries will follow in 2020. We will take pre-orders for all other countries. Please contact us directly via sales@emagine-eye.com. EMAGine will constantly be updating the distributor list and you can subscribe to our newsletter on our website.

Yes, both the device and the Riboker® are CE-marked.

CXL at the slit lamp saves resources. The C-Eye device does not rely on costly infrastructure: blocking an OR for this treatment is no longer required.

The C-Eye device gives you the freedom to treat either at the slit lamp or in the operating theatre using a stand (sold separately)

The C-Eye device can easily be used in different settings, i.e. different clinics.

  • Ability to treat at the slit lamp (time saver)
  • Delivers all intensities currently used in clinical settings
  • Has a thickness-adjusted beam profile
  • Fits both on slit lamps and can be mounted conventionally on a stand in the operating theatre..

Currently, the C-Eye device will be compatible with Haag Streit/ Haag Streit-type slit lamps and with ZEISS/ ZEISS-type slit lamps. Adapters for other models will follow. You find an updated list of all compatible devices on our website.

Yes: using the optional Table Stand Mount, you may attach the device to a table. Adapters for other slit lamp models will follow.

One full charge will allow for at least 5 consecutive treatments. The battery life will last at least 500 charging cycles. This is the typical lifespan of a lithium-ion battery. If needed, the battery can be replaced by EMAGine.

  • Ability to treat at the slit lamp. Saves time and opens opportunities to those colleagues who do not have access to an operating theatre.
  • Delivers all intensities currently used in clinical settings
  • Has a thickness-adjusted beam profile
  • Fits both on slit lamps and can be mounted conventionally on a stand in the operating theatre.
  • The patient will not need to be referred to a larger center but can immediately receive treatment with the primary ophthalmologist.

The kit comprises a single-use cap, a speculum and a single vial of Riboker® CE-marked riboflavin.

Some newer protocols, which are currently under investigation, suggest a beneficial role of pulsed light under certain circumstances. The C-Eye device is prepared to deliver pulsed light treatments, once the clinical body of evidence has become more substantial.

Our riboflavin: Ribo-Ker®

CXL at the slit lamp

There is no need to reapply the drops.

In a scientific study by our group, riboflavin was applied in the horizontal position on the cornea, and then the cornea was suspended vertically for up to 60 minutes. The riboflavin distribution remained virtually the same, with a difference of only 3% between upper and lower cornea after 1 hour.

 

Focusing is easy: you use the optics of the slit lamp and focus on the epithelium of the corneal apex.

Good to know: even when in a defocus of ± 5mm, the increase (when slit lamp too close) and decrease (when slit lamp too far) in intensity is less than 5%. In other words, when the ophthalmologist focuses the image on the iris plane or on the lid plane, the intensity still is fine.

PACK-CXL for infectious keratitis

PACK means “Photoactivated chromophore for infectious keratitis”-CXL. The term was defined by our Chief Scientific Officer Prof. Farhad Hafezi and others at the 2013 CXL Experts Meeting in Zurich, Switzerland

Currently (2019), there are more than 200 scientific publications on the topic on PubMed/MEDLINE, including several Phase II studies. A large, prospective randomized Phase III clinical trial is underway, and initial results confirm that PACK-CXL is highly beneficial for the treatment of infectious keratitis and might be considered as an adjunct or even first line therapy in the future.

PACK-CXL is currently performed off-label. “Off-label” means that a known technique which is valid for a certain indication is used for a different, not yet validated indication. This is similar to the use of Avastin vs Lucentis in age-related macular degeneration (AMD).

PACK-CXL is still a treatment under investigation, so we are unable to make any suggestions on that matter.

Because the infiltrate/ulcer breaks down the epithelium over the infection, all that needs to be done is to remove debris with a dry sponge, where necessary.

The entire cornea should be instilled with riboflavin and irradiated. This is for two reasons:

1) The riboflavin induces the killing effect, but it also acts as a shield from the UV light, by absorbing it. The riboflavin in the periphery of the healthy cornea is protecting the corneal endothelium from too much UV irradiation, and

2) The ulcer is bigger than the visible portion of it (compare it to the top of an iceberg). By irradiating the entire cornea, we ensure that the “invisible” parts of the ulcer are treated, too.

Bacteria, including Staphylococcus aureus, both MSSA and MRSA (antibiotic (Methicillin)-sensitive and antibiotic-resistant), Pseudomonas aeruginosa, and Staphylococcus epidermidis: efficacy 80–99%.

Fungi, including Fusarium and Candida albicans: efficacy 60–70%.

The experimental work required to demonstrate this has not been completed. As a correlate

Solar disinfection (SODIS) is a similar technique to PACK-CXL. In SODIS, water is disinfected using sunlight (energy) and riboflavin. SODIS can kill Herpes simplex virus and acanthamoeba, but the overall total energy is much higher than what we currently use in the cornea.

It certainly helps to kill additional microorganisms and it also increases the resistance of the tissue to digestion. The latter should help keeping the resulting scar smaller than with an antimicrobial treatment alone. More clinical studies are needed to answer this clinical question.

We have tested and published in the laboratory that the efficacy of bacterial killing remains the same when the treatment is accelerated even to 30 mW/cm² for 3 minutes. See here.

Our ongoing multicenter trial is using accelerated protocols between 10 minutes and 5 minutes.

We recommend not to exceed 30 mW/cm² for now.

Daily consultations, continue with standard antimicrobial treatment, treating the open corneal surface.

There currently is too little data to give a clear answer. However, the PACK-CXL energy settings are the same as in classic CXL for keratoconus, and here, we know that a repeated treatment is possible without harming the eye. See here and here.

PACK-CXL is an addition to classic antibiotic treatment. It should be used as early as possible, and it should help to accelerate the time to healing. In Particular, PACK-CXL increases the stromal resistance to digestion. This is something an antibiotic does not do, and this might help keeping the final scar minimal.

We cannot predict the future, but this might become an option someday.

We currently recommend using PACK-CXL in early infection. In early infection, the cornea usually still is thick enough for CXL, even at the area of infection.

In cases where an advanced ulcer is treated, the aim, also in classic treatment, usually is to “calm” the surface and end up in a quiescent scar. Usually, the underlying endothelium is not functional anymore.

If PACK-CXL is used in these cases, the irradiation might indeed harm the part of the endothelium over the thinnest part of the eye, but it will also kill additional pathogen and help preserve the eye as a structure.

A risk/benefit analysis must be made by the doctor: even when using antibiotics only, a quiescent scar would the best outcome possible. Under these circumstances, the doctor has to decide whether he/she wants to use PACK-CXL to further increase chances of calming the situation.

CXL for keratoconus

  • Accelerated 9 mW/cm² for 10 minutes – a solid body of evidence that this setting stops keratoconus progression
  • Accelerated 18 mW/cm² for 5 minutes – mixed results so far. Probably better suited for early keratoconus
  • Accelerated 30–36 mW/cm² for 3 minutes – has no substantial clinical data published so far. Do not use for KC.

Some countries reimburse for CXL treatment, others do not. Please check your national legislation.

A non-compliant patient that does not allow for irradiation at the slit lamp will probably need irradiation in the lying position. The C-Eye device will also have the option to be mounted on a table mount stand, similar to other current CXL devices.

  • Intensity = mW/cm²
  • Fluence (J/cm²) = Intensity x time (seconds)
  • Example: 5.4 J/cm² = 3 mW/cm² x 1800 seconds = 9 mW/cm² x 600 seconds, etc.